Acquisition Impact Epiroc acquired Radlink in 2025, indicating potential alignment with industrial and equipment sectors. This may open cross-selling opportunities into mining and heavy equipment environments that require advanced imaging, AI-guided setup, and integration with existing workflows.

Clinical Validation Radlink3D and Surgeons Checklist software are FDA approved, CE Marked, and ISO 13485 certified with clinical validation for improved accuracy and efficiency. Market opportunities exist in hospitals and orthopedic centers seeking proven, compliant imaging guidance to enhance surgical outcomes.

Strategic Partnerships Product development with surgeon advisory team suggests a strong channel for partnerships with private practices and academic centers. Leverage surgeon-led advocacy to obtain references, case studies, and early-adopter deployments.

Multi‑Platform Reach Radlink software runs on multiple hardware platforms including third‑party mobile C-arms (Siemens Cios, Philips Zenition) and in‑center imaging environments. This flexibility supports upsell of AI software across diverse operating room setups and instrumentation.

Growth Potential Current revenue range and global regulatory approvals position Radlink for expansion in orthopedics, radiology, and spine markets. Target expansions could include private clinics, outpatient centers, and international markets requesting validated imaging guidance and surgical AI analytics.